CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 64 enrolled
Drug / intervention
Isoquercetindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02195232
NCT02195232Phase 3Completed
CompareCT.gov

Randomized, Placebo-controlled, Double-blind Phase II/III Trial of Oral Isoquercetin to Prevent Venous Thromboembolic Events in Cancer Patients.

Jeffrey Zwicker, MD·interventional·Posted Jul 21, 2014·Updated Mar 3, 2021

In Brief

A Phase 3 clinical trial evaluating Isoquercetin for Thromboembolism of Vein VTE in Colorectal Cancer and 2 related conditions. Completed, enrolled 64 participants across 11 sites.

Detailed Summary

This research study is evaluating a drug called isoquercetin to prevent venous thrombosis (blood clots), in participants who have pancreas, non small cell lung cancer or colorectal cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThromboembolism of Vein VTE in Colorectal Cancer, Thromboembolism of Vein in Pancreatic Cancer, Thromboembolism of Vein in Non-small Cell Lung Cancer
CountriesUnited States
CollaboratorsQuercegen Pharmaceuticals, National Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 21, 2014
Enrollment StartJan 1, 2015
Primary CompletionDec 1, 2018
Study CompletionOct 22, 2019
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 11.9 years ago

Interventions

Isoquercetindrug